SCHEMBL20837272

SCHEMBL20837272

COc1ccc(N)c2ocnc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 2/20 0.40
IDO1 P14902 1/20 0.39
EP300 Q09472 1/20 0.38
KAT8 Q9H7Z6 1/20 0.38
ALDH1A1 P00352 7/20 0.37
CYP3A4 P08684 4/20 0.37
TDP1 Q9NUW8 4/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MAPT P10636 3/20 0.37
THRB P10828 2/20 0.37
GAA P10253 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 1/20 0.37
BLM P54132 1/20 0.37
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20837263 0.82 ALDH1A1 (0.43) NQO2ALDH1A1TDP1HSD17B10MAPT
SCHEMBL20837283 0.80 NQO2 (0.41) NQO2ALDH1A1TSHRHSD17B10MAPT
SCHEMBL6952678 0.79 NQO2 (0.49) NQO2ALDH1A1MAPTKDM4EMAPK1
SCHEMBL20837299 0.78 NQO2 (0.37) NQO2ALDH1A1TSHRMAPTTHRB
SCHEMBL20837137 0.76 NNMT (0.40) ALDH1A1TDP1HSD17B10GAAKDM4E
SCHEMBL24819184 0.76 NOS3 (0.33) ALDH1A1CYP3A4TDP1TSHRLMNA
SCHEMBL20837066 0.75 MCL1 (0.38) NQO2ALDH1A1HSD17B10KDM4ENPC1
SCHEMBL20837300 0.75 G6PD (0.43) ALDH1A1CYP3A4TDP1TSHRHSD17B10
SCHEMBL20837396 0.75 ALDH1A1 (0.44) NQO2ALDH1A1GAAKDM4EIMPDH2
SCHEMBL20837398 0.73 LMNA (0.49) NQO2ALDH1A1CYP3A4TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 US disclosed
WO-2019055750-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF Aduro Biotech, Inc. (US) 2019-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 NQO2 53/4885IDO1 487/4885EP300 2586/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 NQO2 53/4885IDO1 487/4885EP300 2586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.